← All drugs
Drug · FAERS side-effect profile with label screen

Leflunomide side effects: what 104,025 FDA adverse event reports show

Leflunomide · 1,269 reaction terms · 1,095,210 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Antirheumatic Agent

FDA label (Established Pharmacologic Class)

Who reports

104,025 reports · 82% serious · 9,331 with death outcome · 82% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Leflunomide tablets are indicated for the treatment of adults with active rheumatoid arthritis (RA). Leflunomide is a pyrimidine synthesis inhibitor indicated for the treatment of adults with active rheumatoid arthritis.

FDA label, Indications and Usage

What it is

Leflunomide is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline.

PubChem CID 3899 (ChEBI)

Boxed warning

EMBRYO-FETAL TOXICITY and HEPATOTOXICITY WARNING: EMBRYO-FETAL TOXICITY and HEPATOTOXICITY Embryo-Fetal Toxicity Leflunomide is contraindicated for use in pregnant women because of the potential for fetal harm. Teratogenicity and embryo-lethality occurred in animals administered leflunomide at doses lower than the human exposure level.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled adverse reaction 1Labeled (related wording) 4Likely indication confounding 1Reporting / coding artifact 2Lab value / disease marker 10Not in label — unassessed 22
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,229 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Anti-cyclic citrullinated peptide antibody positive6,1271,365.5
1,273.0–1,464.7ROR 1,450.9 · calibrated p 3e-19 ✓
173.6 EB05 170.0 · IC025 +7.4
3/3 methods agree
Lab value / disease markerserious PRR 121.6 · 92% clinicianno trial arm names this drug
Rheumatoid factor negative1511,245.1
809.4–1,915.4ROR 1,246.9 · calibrated p 4e-17 ✓
168.0 EB05 146.7 · IC025 +6.5
3/3 methods agree
Reporting / coding artifactserious n=151 · ♀ 49% (drug 82%)no trial arm names this drug
Red blood cell sedimentation rate219734.6
551.1–979.2ROR 736.1 · calibrated p 3e-15 ✓
154.6 EB05 138.2 · IC025 +6.6
3/3 methods agree
Lab value / disease markerserious n=219 · 91% clinicianno trial arm names this drug
Rheumatoid factor positive4,432694.5
652.6–739.0ROR 725.3 · calibrated p 1e-15 ✓
154.7 EB05 150.9 · IC025 +7.2
3/3 methods agree
Lab value / disease markerserious n=4,428 · 91% clinicianno trial arm names this drug
Pemphigus9,382642.9
616.9–670.0ROR 706.5 · calibrated p 1e-15 ✓
152.0 EB05 149.5 · IC025 +7.2
3/3 methods agree
Not in label — unassessedserious PRR 106.5no trial arm names this drug
Swollen joint count increased2,321606.0
558.4–657.6ROR 619.8 · calibrated p 6e-15 ✓
149.8 EB05 144.7 · IC025 +7.1
3/3 methods agree
Lab value / disease markerserious n=2,319 · 94% clinicianno trial arm names this drug
Duodenal ulcer perforation5,149485.9
462.0–511.1ROR 511.2 · calibrated p 5e-14 ✓
141.3 EB05 138.1 · IC025 +7.1
3/3 methods agree
Not in label — unassessedserious PRR 98.5 · 93% clinicianno trial arm names this drug
C-reactive protein620444.6
385.8–512.2ROR 447.2 · calibrated p 2e-13 ✓
137.1 EB05 128.2 · IC025 +6.8
3/3 methods agree
Lab value / disease markerserious n=620 · 95% clinicianno trial arm names this drug
Deep vein thrombosis postoperative1,325429.2
390.0–472.2ROR 434.7 · calibrated p 3e-13 ✓
135.9 EB05 129.8 · IC025 +6.9
3/3 methods agree
Not in label — unassessedserious n=1,325 · 92% clinicianno trial arm names this drug
Lupus vulgaris781392.3
347.6–442.7ROR 395.2 · calibrated p 7e-13 ✓
131.8 EB05 124.2 · IC025 +6.8
3/3 methods agree
Not in label — unassessedserious n=781 · 95% clinicianno trial arm names this drug
Anti-cyclic citrullinated peptide antibody431374.1
318.7–439.2ROR 375.7 · calibrated p 1e-12 ✓
129.4 EB05 119.4 · IC025 +6.7
3/3 methods agree
Lab value / disease markerserious n=431 · 94% clinicianno trial arm names this drug
Swollen joint count158367.9
282.6–478.8ROR 368.4 · calibrated p 3e-12 ✓
127.4 EB05 111.6 · IC025 +6.3
3/3 methods agree
Not in label — unassessedserious n=158 · 100% clinicianno trial arm names this drug
Hand deformity8,389367.0
354.1–380.3ROR 399.1 · calibrated p 6e-13 ✓
129.2 EB05 126.9 · IC025 +7.0
3/3 methods agree
Not in label — unassessedserious PRR 97.9no trial arm names this drug
Facet joint syndrome2,008360.0
334.6–387.3ROR 367.0 · calibrated p 1e-12 ✓
128.2 EB05 123.5 · IC025 +6.9
3/3 methods agree
Not in label — unassessedserious n=2,008 · 95% clinicianno trial arm names this drug
Grip strength146348.1
265.9–455.7ROR 348.6 · calibrated p 5e-12 ✓
124.8 EB05 108.7 · IC025 +6.2
3/3 methods agree
Not in label — unassessedserious n=146 · 100% clinicianno trial arm names this drug
C-reactive protein abnormal3,855309.0
293.9–324.9ROR 320.9 · calibrated p 5e-12 ✓
121.2 EB05 118.0 · IC025 +6.8
3/3 methods agree
Lab value / disease markerserious n=3,854no trial arm names this drug
Granuloma skin496304.8
265.0–350.7ROR 306.3 · calibrated p 1e-11 ✓
120.1 EB05 111.4 · IC025 +6.6
3/3 methods agree
Not in label — unassessedserious n=496no trial arm names this drug
Musculoskeletal deformity136277.5
213.9–360.0ROR 277.8 · calibrated p 4e-11 ✓
114.3 EB05 99.0 · IC025 +6.1
3/3 methods agree
Not in label — unassessedserious n=136 · 100% clinicianno trial arm names this drug
Synovitis10,363275.3
267.4–283.5ROR 305.7 · calibrated p 8e-12 ✓
115.7 EB05 113.8 · IC025 +6.8
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 84.3no trial arm names this drug
Red blood cell sedimentation rate abnormal1,321267.9
246.6–290.9ROR 271.3 · calibrated p 3e-11 ✓
114.2 EB05 109.1 · IC025 +6.7
3/3 methods agree
Lab value / disease markerserious n=1,320no trial arm names this drug
X-ray abnormal945228.9
208.5–251.3ROR 231.0 · calibrated p 1e-10 ✓
106.5 EB05 100.9 · IC025 +6.6
3/3 methods agree
Lab value / disease markerserious n=945 · 93% clinicianno trial arm names this drug
Adjustment disorder with depressed mood1,042217.5
199.2–237.5ROR 219.7 · calibrated p 2e-10 ✓
104.0 EB05 98.8 · IC025 +6.5
3/3 methods agree
Not in label — unassessedserious n=1,041 · 95% clinicianno trial arm names this drug
Muscle injury4,227215.9
206.8–225.5ROR 225.0 · calibrated p 1e-10 ✓
103.7 EB05 101.1 · IC025 +6.6
3/3 methods agree
Not in label — unassessedserious PRR 78.5 · 94% clinicianno trial arm names this drug
Helicobacter infection5,181210.1
202.1–218.3ROR 221.0 · calibrated p 2e-10 ✓
102.4 EB05 100.1 · IC025 +6.6
3/3 methods agree
Not in label — unassessedserious PRR 75.5 · 93% clinicianno trial arm names this drug
Dislocation of vertebra1,106200.8
184.7–218.3ROR 203.0 · calibrated p 4e-10 ✓
100.0 EB05 95.2 · IC025 +6.5
3/3 methods agree
Not in label — unassessedserious n=1,106 · 94% clinicianno trial arm names this drug
Hypocholesterolaemia152197.9
158.1–247.8ROR 198.2 · calibrated p 7e-10 ✓
98.3 EB05 85.8 · IC025 +6.0
3/3 methods agree
Not in label — unassessedserious n=152 · 100% clinicianno trial arm names this drug
Sleep disorder due to general medical condition, insomnia type3,116190.4
181.3–199.9ROR 196.2 · calibrated p 5e-10 ✓
97.5 EB05 94.6 · IC025 +6.5
3/3 methods agree
Not in label — unassessedserious n=3,113 · 93% clinicianno trial arm names this drug
Folliculitis4,922184.7
177.8–192.0ROR 193.9 · calibrated p 5e-10 ✓
96.0 EB05 93.8 · IC025 +6.5
3/3 methods agree
Not in label — unassessedserious PRR 78.6 · 94% clinicianno trial arm names this drug
Bone erosion1,595166.0
155.3–177.3ROR 168.5 · calibrated p 2e-9 ✓
90.6 EB05 87.0 · IC025 +6.4
3/3 methods agree
Not in label — unassessedserious n=1,590no trial arm names this drug
Retinitis683140.1
127.0–154.5ROR 141.0 · calibrated p 8e-9 ✓
82.3 EB05 77.2 · IC025 +6.2
3/3 methods agree
Not in label — unassessedserious n=683 · 94% clinicianno trial arm names this drug
Joint laxity123138.3
109.9–174.1ROR 138.5 · calibrated p 1e-8 ✓
80.8 EB05 69.5 · IC025 +5.6
3/3 methods agree
Not in label — unassessedserious n=122no trial arm names this drug
Rheumatoid nodule1,120136.1
126.1–146.8ROR 137.5 · calibrated p 1e-8 ✓
80.9 EB05 77.0 · IC025 +6.2
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=1,102no trial arm names this drug
Contraindicated product administered11,938132.5
129.6–135.5ROR 149.6 · calibrated p 5e-9 ✓
79.8 EB05 78.6 · IC025 +6.3
3/3 methods agree
Reporting / coding artifactage-adj. PRR 107.6 · serious PRR 68.7no trial arm names this drug
Subcutaneous drug absorption impaired213129.7
109.1–154.2ROR 130.0 · calibrated p 2e-8 ✓
78.2 EB05 69.8 · IC025 +5.8
3/3 methods agree
Not in label — unassessedserious n=213 · 100% clinicianno trial arm names this drug
Blood parathyroid hormone decreased576127.2
114.6–141.2ROR 127.9 · calibrated p 2e-8 ✓
77.6 EB05 72.5 · IC025 +6.1
3/3 methods agree
Lab value / disease markerserious n=576no trial arm names this drug
Pericarditis6,347124.4
120.6–128.3ROR 132.4 · calibrated p 1e-8 ✓
76.7 EB05 75.2 · IC025 +6.2
3/3 methods agree
Not in label — unassessedserious PRR 54.0 · 93% clinicianno trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Liver injury14,28010.09.8–10.1signal
Interstitial lung disease4,0618.98.6–9.1signal
Tendon disorder8314.54.2–4.8signal
Serious infection15,3904.14.0–4.1signal
Opportunistic infection2,4773.73.6–3.9signal
Hyperglycaemia / diabetes5,2923.13.0–3.2signal
Anaphylaxis / angioedema1,4802.42.3–2.5signal
Depression3,2912.42.3–2.5signal
Fall / fracture3,7492.01.9–2.1raised
Pancreatitis6961.71.6–1.9raised
Anaemia2,2341.51.4–1.6raised
Malignancy2,5641.41.3–1.4raised
Venous thromboembolism1,4601.41.3–1.4raised
Osteonecrosis3761.31.2–1.5raised
Rhabdomyolysis / myopathy4961.21.1–1.3raised
Kidney injury2,7521.21.2–1.3raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Leflunomide only as a background or rescue medication (NCT00476996, NCT01646385); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug ineffective (drug did not work)37,3825.9
5.8–5.9ROR 8.6 · calibrated p 0.053
5.7 EB05 5.7 · IC025 +2.5
3/3 methods agree
Reporting / coding artifactage-adj. PRR 6.4 · serious PRR 10.2no trial arm names this drug
Rheumatoid arthritis25,33858.1
57.4–58.9ROR 76.5 · calibrated p 8e-7 ✓
45.2 EB05 44.7 · IC025 +5.5
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 46.1 · serious PRR 37.7no trial arm names this drug
Pain20,4696.9
6.8–7.0ROR 8.4 · calibrated p 0.058
6.7 EB05 6.6 · IC025 +2.7
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 6.3 · serious PRR 7.0no trial arm names this drug
Arthralgia (joint pain)17,3928.8
8.7–8.9ROR 10.4 · calibrated p 0.029 ✓
8.5 EB05 8.4 · IC025 +3.1
3/3 methods agree
Not in label — unassessedage-adj. PRR 7.8 · serious PRR 10.2no trial arm names this drug
Drug intolerance15,93539.9
39.3–40.5ROR 46.9 · calibrated p 2e-5 ✓
33.4 EB05 32.9 · IC025 +5.0
3/3 methods agree
Reporting / coding artifactage-adj. PRR 42.7 · serious PRR 37.1no trial arm names this drug
Joint swelling15,92530.6
30.1–31.1ROR 36.0 · calibrated p 1e-4 ✓
26.6 EB05 26.3 · IC025 +4.7
3/3 methods agree
Not in label — unassessedage-adj. PRR 25.9 · serious PRR 31.2no trial arm names this drug
Rash13,7236.6
6.5–6.7ROR 7.4 · calibrated p 0.084
6.4 EB05 6.3 · IC025 +2.6
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 6.2 · serious PRR 9.4no trial arm names this drug
Off label use (used outside approved label)12,2162.9
2.8–2.9ROR 3.1 · calibrated p 0.591
2.8 EB05 2.8 · IC025 +1.5
3/3 methods agree
Reporting / coding artifactage-adj. PRR 2.9 · serious PRR 3.6no trial arm names this drug
Abdominal discomfort12,04615.6
15.3–15.9ROR 17.5 · calibrated p 0.004 ✓
14.5 EB05 14.3 · IC025 +3.8
3/3 methods agree
Not in label — unassessedage-adj. PRR 12.7 · serious PRR 22.2no trial arm names this drug
Alopecia (hair loss)11,99913.0
12.8–13.3ROR 14.6 · calibrated p 0.008 ✓
12.3 EB05 12.1 · IC025 +3.6
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 9.8 · serious PRR 17.5no trial arm names this drug
Contraindicated product administered11,938132.5
129.6–135.5ROR 149.6 · calibrated p 5e-9 ✓
79.8 EB05 78.6 · IC025 +6.3
3/3 methods agree
Reporting / coding artifactage-adj. PRR 107.6 · serious PRR 68.7no trial arm names this drug
Arthropathy11,10050.0
49.0–51.0ROR 55.8 · calibrated p 7e-6 ✓
40.1 EB05 39.5 · IC025 +5.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 44.9 · serious PRR 33.9no trial arm names this drug
Condition aggravated10,6597.3
7.2–7.5ROR 8.1 · calibrated p 0.065
7.1 EB05 7.0 · IC025 +2.8
3/3 methods agree
Reporting / coding artifactage-adj. PRR 6.8 · serious PRR 7.3no trial arm names this drug
Swelling10,56325.6
25.1–26.1ROR 28.4 · calibrated p 3e-4 ✓
22.8 EB05 22.4 · IC025 +4.5
3/3 methods agree
Not in label — unassessedage-adj. PRR 20.7 · serious PRR 25.4no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Leflunomide ↔ Hepatotoxicity.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Leflunomide?

In FDA FAERS, the most frequently co-reported reaction terms for Leflunomide are rheumatoid arthritis, pain, arthralgia, joint swelling, fatigue, rash. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Leflunomide have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: EMBRYO-FETAL TOXICITY and HEPATOTOXICITY WARNING: EMBRYO-FETAL TOXICITY and HEPATOTOXICITY Embryo-Fetal Toxicity Leflunomide is contraindicated for use in pregnant women because of the potential for fetal harm. Teratogenicity and embryo-lethality occurred in animals administered leflunomide at doses lower than the human exposure level.

Do FAERS signals prove that Leflunomide causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.